Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A2 | P23975 | 1/20 | 0.46 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 4/20 | 0.40 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.40 |
| ▸ | GLS | O94925 | 1/20 | 0.39 |
| ▸ | PLG | P00747 | 1/20 | 0.39 |
| ▸ | PLAU | P00749 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.39 |
| ▸ | KRAS | P01116 | 1/20 | 0.38 |
| ▸ | MEN1 | O00255 | 2/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | ERN1 | O75460 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1098394 | 0.76 | CYP19A1 (0.51) | SLC6A2CYP19A1MAPTCYP1A2GLS | |
| SCHEMBL5176754 | 0.74 | NOTUM (0.51) | SLC6A2CYP19A1MAPTCYP1A2ALDH1A1 | |
| SCHEMBL29642981 | 0.74 | NOTUM (0.51) | SLC6A2CYP19A1MAPTCYP1A2ALDH1A1 | |
| SCHEMBL28030880 | 0.72 | SLC6A2 (0.51) | SLC6A2CYP19A1MAPTCYP1A2GLS | |
| SCHEMBL10102889 | 0.72 | PRKCI (0.55) | MAPTPLAUALDH1A1TDP1LMNA | |
| SCHEMBL28281973 | 0.72 | SLC6A2 (0.51) | SLC6A2CYP19A1MAPTCYP1A2GLS | |
| SCHEMBL3224421 | 0.72 | SLC6A2 (0.51) | SLC6A2CYP19A1MAPTCYP1A2GLS | |
| SCHEMBL28142780 | 0.72 | SLC6A2 (0.51) | SLC6A2CYP19A1MAPTCYP1A2GLS | |
| SCHEMBL3218015 | 0.72 | SLC6A2 (0.51) | SLC6A2CYP19A1MAPTCYP1A2GLS | |
| SCHEMBL415582 | 0.72 | HTR2A (0.44) | SLC6A2KRAS |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8093285-B2 | Aminopiperidinyl derivatives and uses thereof | ROCHE PALO ALTO LLC (US) | 2012-01-10 | — | — | US | disclosed |
| US-20090247568-A1 | AMINOPIPERIDINYL DERIVATIVES AND USES THEREOF | ROCHE PALO ALTO LLC | 2009-10-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090247568-A1 | AMINOPIPERIDINYL DERIVATIVES AND USES THEREOF | MAOB, ADORA2B, HTR1B | SLC6A2 8/4885CYP19A1 502/4885MAPT 2418/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.